For the quarter ended Sept. 30, Cepheid reported preliminary revenue of approximately $126.5 million, shy of the Wall Street estimate of $127.8 million.
The lower preliminary revenue was due to lower than expected sales of its desktop instruments and performance in Europe and Asia Pacific.
The company also said that it expects to report fiscal 2015 revenues and EPS at the low end of its previously stated guidance range.
The Danish firm's research business grew 24 percent and its North American revenues grew 52 percent.
The firm's revenues were hit by currency translation and differences in the timing of test reimbursement compared with the previous year's quarter.
The company provided preliminary 2015 revenue guidance of $175 million to $190 million.
The company's chairman and CEO said that PositiveID has a sizeable backlog and pipeline of revenue opportunities for 2015.
During its second quarter earnings call, Myriad officials detailed the market prospects for its tumor and germline BRACAnalysic CDx tests.
The preliminary revenues are on par with the average analyst estimate of $33.3.
The company initiated guidance for 2015 at a range of $4.35 to $4.45 per share.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.